Fresenius SE & Co. (OTCMKTS:FSNUY) Reaches New 12-Month High - Should You Buy?

Key Points

• Fresenius SE & Co. shares reached a new 52-week high of $13.72, with the last trading price at $13.60.
• Morgan Stanley has reaffirmed an "overweight" rating on the stock, with an overall average rating of "Buy" among analysts.
• The company recently raised its dividend to $0.1827, resulting in a dividend yield of 148.0%, with a payout ratio of 33.96%.

Shares of Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $13.72 and last traded at $13.60, with a volume of 8529 shares changing hands. The stock had previously closed at $13.63.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley reissued an "overweight" rating on shares of Fresenius SE & Co. in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy".

Fresenius SE & Co. Stock Performance

The stock has a 50 day simple moving average of $12.53 and a 200 day simple moving average of $11.64. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 1.43.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $0.02. The company had revenue of $6.48 billion for the quarter, compared to analysts' expectations of $5.83 billion. Fresenius SE & Co. had a return on equity of 9.33% and a net margin of 5.09%. As a group, equities research analysts predict that Fresenius SE & Co. will post 0.79 earnings per share for the current fiscal year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.